Ahn, Soyon
Nesbit, Maya O.
Zou, Haiyan
Vacca, Giada
Axerio-Cilies, Peter
Van Sung, Tran
Phillips, Anthony G.
Funding for this research was provided by:
Canadian Institutes of Health Research (IOP 101025)
Natural Sciences and Engineering Research Council of Canada (NSERC-RGPIN-2016-043)
Article History
Received: 17 September 2020
Accepted: 17 November 2020
First Online: 4 December 2020
Competing interests
: A.G.P. holds a US patent entitled “Tetrahydroprotoberbine Compounds and Uses Thereof” in the Treatment of Neurological, Psychiatric and Neurodegenerative Diseases. United States. US20150306092. A.G.P. also holds shares in Resilience Biosciences Inc., Canada., focused on tetrahydroprotoberberine drug development. T.V.S. holds shares in Named Pharmaceuticals MTV Ltd., Vietnam. The Institute of Chemistry, Vietnam Academy of Science and Technology holds a patent on Heantos-4 in Vietnam. S.A., M.O.N., H.Z., G.V. and P.A.-C. have no conflicts of interest to declare.